GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline
The U.K. drugmaker is targeting annual savings of $2.52 billion by 2029, as Chief Executive Luke Miels outlined his roadmap to hit the company’s 2031 sales target.
The U.K. drugmaker is targeting annual savings of $2.52 billion by 2029, as Chief Executive Luke Miels outlined his roadmap to hit the company’s 2031 sales target.